GSK at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

GSK takes part in 2 sessions at ACT 2026 in San Antonio. Its sessions cover newer methods in safety assessment, including new approach methods for judging the immune safety of immunotherapies and an industry view of advanced carcinogenicity risk assessment.

OrganizationACT 2026 Attendance
GSK
London, UK
gsk.com
Pharmaceutical companies
Global pharmaceutical company developing medicines and vaccines in infectious disease, HIV, respiratory, immunology and oncology.
Talk
Sun Nov 15
1:30pm–1:50pm
Part of Immunotherapies and Collaborative Approaches to Immunosafety Assessment (CE6)
Evaluation of NAMs for Immunosafety and How to Incorporate Them into the Development of Immunotherapies (CE6-2)
Immunotoxicology · New approach methods
Talk
Wed Nov 18
11:15am–11:45am
Part of The Future of Nonclinical Carcinogenicity Testing: NAMs in a Weight-of-Evidence Paradigm Shift (S15)
Industry Perspectives on Advanced Methods for Carcinogenicity Risk Assessment (S15-5)
Genetic toxicology

Explore the full ACT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Antonio. Leave your work email and we’ll be in touch.

Privacy

Download the full ACT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from GSK

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction